Navigation Links
LifeNet Health and Soluble Systems Announce Partnership to Launch TheraSkin(TM)
Date:3/5/2010

nced biologics wound care market. Growing at better than 15 percent per year, the advanced biologics market is one of the fastest growing segments of the $5 billion global wound care market.

TheraSkin™ is a cryo-preserved human skin allograft with both epidermis and dermis layers. When applied to a wound that is not healing properly, TheraSkin™ can jumpstart the healing process. TheraSkin™ provides a supply of growth factors, cytokines and collagen to promote wound healing. TheraSkin™ is a superior alternative to Live Skin Equivalent (LSE) products currently used to help heal chronic wounds.  Like LSE's, TheraSkin™ provides necessary growth factors and cytokines. Unlike LSE's, TheraSkin™ provides a large quantity of essential collagens in appropriate ratios to support healing.

Importantly, the launch of TheraSkin™ provides health care practitioners a new weapon in the battle to reduce health care costs. Depending on size, TheraSkin™ fees are 50 percent to 70 percent less than LSE's now on the market and can ultimately save the national healthcare system hundreds of millions of dollars.

Allan Staley, President of Soluble Systems, LLC comments, "TheraSkin™ is a major addition to our product line and is synergistic to T
'/>"/>

SOURCE LifeNet Health
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. LifeNet Health and IMS Announce Partnership
2. LifeNet Health and LOPA Announce a Partnership
3. LifeNet Health Saves 303 Lives and Restores Health to 265,967 Patients in 2007
4. LifeNet Health(R) Unveils New Biomedical Spine Implant
5. ETEX and LifeNet Health, Inc. Enter Agreement
6. LifeNet Health Chief Scientific Officer Wins Award
7. LifeNet Health Introduces New Sports Medicine Bio-Implants
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
10. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... VRUS ) management will present at Cowen & ... 2008 at Boston Marriott,Copley Place in Boston, MA. Schaefer ... the company on Tuesday, March 18, 2008,from 3:55 PM ... access a simultaneous webcast of Mr. Price,s overview of ...
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") today ... 31, 2007. All results are in U.S.,dollars and prepared ... ended December 31, 2007, was $20.3 million or,$1.04 per ... $2.38,per basic and diluted share in 2006. The substantial ...
... MannKind,Corporation (Nasdaq: MNKD ) today issued the ... MannKind is absolutely committed to the continued development ... our small,patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin ... more closely matches the pattern,of insulin secretion seen ...
Cached Biology Technology:Pharmasset to Present at Cowen & Company's Health Care Conference on Tuesday, March 18th 2Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... breakthrough in sensing at Rice University could make finding signs ... light. The technique reported in the Journal ... better medications to treat the devastating disease. The lab ... naturally attach themselves to a collection of beta amyloid proteins ...
... including stomach, liver and colon, are far more common in ... in lifestyle, such as diet and smoking, may account for ... rooted in basic biological differences between men and women. ... that treating male mice with estrogen dramatically lowers their rates ...
... COLLEGE PARK, Md. -- A new University of ... the 2009 flu pandemic (H1N1) and a common type of ... flu viruses -- with the potential for creating a new ... but University of Maryland virologist Daniel Perez, who directed the ...
Cached Biology News:Molecules 'light up' Alzheimer's roots 2Molecules 'light up' Alzheimer's roots 3Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3When well-known flu strains 'hook up' dangerous progeny can result 2When well-known flu strains 'hook up' dangerous progeny can result 3
... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
... 'Agilents GeneSpring Workgroup solution is ... managing and mining expression data in ... and is deployed in over 40 ... research organizations worldwide. GeneSpring Workgroup streamlines ...
... proteomic scale kinase profiling, quantitative measurement ... discovery research built on the flexible ... platform. These microarrays are available as ... Substrate - Peptide Microarray Service. ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences are ... is (amino to carboxy terminus): S(21) - S - M - ... - E - A - I - D - K - ... This peptide may be used for neutralization and control ...
Biology Products: